Private company
Helus Pharma
Canadian pharmaceutical company
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines. The company's drug candidates include psilocybin (HLP001; CYB001), HLP002 (CYB002; discontinued), deupsilocin (HLP003; CYB003; psilocin-d10; deuterated psilocin), deudimethyltryptamine (HLP004; CYB004; DMT-d10; deuterated dimethyltryptamine (DMT)), HLP005 (CYB005; deuterated phenethylamine derivative), and HLP006 (CYB006).2 Wikipedia text CC BY-SA 4.0
Last updated Oct 21, 2026.
Overview
- Industrybiotechnology, pharmaceutical industry1
- Websitewww.helus.com
See how the biggest companies compare on our leaderboards
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines. The company's drug candidates include psilocybin (HLP001; CYB001), HLP002 (CYB002; discontinued), deupsilocin (HLP003; CYB003; psilocin-d10; deuterated psilocin), deudimethyltryptamine (HLP004; CYB004; DMT-d10; deuterated dimethyltryptamine (DMT)), HLP005 (CYB005; deuterated phenethylamine derivative), and HLP006 (CYB006).2
Timeline
- 2019Founded Founded1
Links
- Websitewww.helus.com1
- WikipediaHelus Pharma
- WikidataQ132476994
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataHelus Pharma on Wikidata
- 2WikipediaHelus Pharma on Wikipedia